

References

I-5066

1. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol*. May 10 2019; 37(14): 1228-1263. PMID 30932732.
2. National Cancer Institute. Cancer Stat Facts: Myeloma. <https://seer.cancer.gov/statfacts/html/mulmy.html>. Accessed January 20, 2023.
3. Key Statistics About Multiple Myeloma. <https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html>. Accessed January 20, 2023.
4. Manier S, Salem KZ, Liu D, et al. Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. *Am Soc Clin Oncol Educ Book*. 2016; 35: e400-6. PMID 27249747.
5. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*. Aug 2016; 17(8): e328-e346. PMID 27511158.
6. NCCN Clinical Practice Guidelines in Oncology- Multiple Myeloma Version 3.2023- Dec 8, 2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed January 20, 2023.
7. Pick M, Vainstein V, Goldschmidt N, et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. *Eur J Haematol*. May 2018; 100(5): 494-501. PMID 29453884.
8. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. Sep 2019; 33(9): 2266-2275. PMID 30858549.

9. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*. Feb 2020; 21(2): 207-221. PMID 31859245.
10. Holstein SA, Suman VJ, McCarthy PL. Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. *Curr Hematol Malig Rep*. Feb 2019; 14(1): 31-38. PMID 30661162.
11. Cartier S, Zhang B, Rosen VM, et al. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data. *Oncol Res Treat*. 2015; 38(3): 88-94. PMID 25792079.
12. Prescribing Label: Abecma (idecabtagene vicleucel), suspension for intravenous infusion. Available at https://packageinserts.bms.com/pi/pi_abecma.pdf. Accessed on January 20, 2023.
13. Lee DW, Santomaso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*. Apr 2019; 25(4): 625-638. PMID 30592986.
14. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *N Engl J Med*. Feb 25 2021; 384(8): 705-716. PMID 33626253.
15. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. Jul 24 2021; 398(10297): 314-324. PMID 34175021.
16. Prescribing Label: Carvykti (ciltacabtagene autoleucel) suspension for intravenous infusion. Available at <https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/CARVYKTI-pi.pdf>. Accessed January 20, 2023.
17. Institute for Clinical and Economic Review. Evidence Report: Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for

Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma. April 5, 2021 [https://34eyj51jerf417itp82ufdoe-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/ICER Multiple-Myeloma Evidence-Report_040521.pdf](https://34eyj51jerf417itp82ufdoe-wpengine.netdna-ssl.com/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Evidence-Report_040521.pdf). Accessed January 20, 2023.